Antibiotic complications during the treatment of Mycobacterium ulcerans disease in Australian patients
Sign Up to like & getrecommendations! Published in 2017 at "Internal Medicine Journal"
DOI: 10.1111/imj.13511
Abstract: Antibiotics are the recommended first‐line treatment for Mycobacterium ulcerans disease. Antibiotic toxicity is common in Australian patients, yet antibiotic complication rates and their risk factors have not been determined. read more here.
Keywords: mycobacterium ulcerans; treatment mycobacterium; ulcerans disease; australian patients ... See more keywords
High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease
Sign Up to like & getrecommendations! Published in 2018 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01478-18
Abstract: Buruli ulcer (BU), caused by Mycobacterium ulcerans, is a neglected tropical skin and soft tissue infection that is associated with disability and social stigma. The mainstay of BU treatment is an 8-week course of rifampin… read more here.
Keywords: shorter oral; mycobacterium ulcerans; treatment; ulcerans disease ... See more keywords
Susceptibility to Mycobacterium ulcerans Disease (Buruli ulcer) Is Associated with IFNG and iNOS Gene Polymorphisms
Sign Up to like & getrecommendations! Published in 2017 at "Frontiers in Microbiology"
DOI: 10.3389/fmicb.2017.01903
Abstract: Buruli ulcer (BU) is a chronic necrotizing disease of the skin and subcutaneous fat tissue. The causative agent, Mycobacterium ulcerans, produces mycolactone, a macrolide toxin, which causes apoptosis of mammalian cells. Only a small proportion… read more here.
Keywords: buruli ulcer; ulcerans disease; mycobacterium ulcerans; susceptibility mycobacterium ... See more keywords